Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults

por Tjon, Jennifer M.-L., Langemeijer, Saskia M. C., Halkes, Constantijn J. M.
Publicado 2021

The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs

por ter Avest, Mendy, Langemeijer, Saskia M.C., Schols, Saskia E.M., Burger, David M., van de Kar, Nicole C.A.J., Blijlevens, Nicole M.A., Kievit, Wietske, ter Heine, Rob
Publicado 2021

Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria

por Schaap, Charlotte C.M., Schols, Saskia E.M., Preijers, Frank W.M.B., de Jonge, Emiel, Laarakkers, Coby M.M., Jansen, Joop H., Blijlevens, Nicole M.A., Swinkels, Dorine W., Langemeijer, Saskia M.C.
Publicado 2023

Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML

por Tiso, F., Koorenhof-Scheele, T. N., Huys, E., Martens, J. H. A., de Graaf, A. O., van der Reijden, B. A., Langemeijer, S. M. C., Preijers, F. W. M. B., Kroeze, L. I., Jansen, J. H.
Publicado 2022

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

por Peipert, John Devin, Kulasekararaj, Austin G., Gaya, Anna, Langemeijer, Saskia M. C., Yount, Susan, Gonzalez-Fernandez, F. Ataulfo, Ojeda Gutierrez, Emilio, Martens, Christa, Sparling, Amy, Webster, Kimberly A., Cella, David, Tomazos, Ioannis, Ogawa, Masayo, Piatek, Caroline I., Wells, Richard, Sicre de Fontbrune, Flore, Röth, Alexander, Mitchell, Lindsay, Hill, Anita, Kaiser, Karen
Publicado 2020